NOVARTIS has confirmed that supplies of hormone replacement therapy patches continue to be unreliable due to manufacturing issues, with the company anticipating a return to stable supply of items such as Estradot and Estalis by the middle of 2017.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Apr 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Apr 17